Lack of MTTP Activity in Pluripotent Stem Cell-Derived Hepatocytes and Cardiomyocytes Abolishes apoB Secretion and Increases Cell Stress

Cell Reports
Ying LiuEdward E Morrisey

Abstract

Abetalipoproteinemia (ABL) is an inherited disorder of lipoprotein metabolism resulting from mutations in microsomal triglyceride transfer protein (MTTP). In addition to expression in the liver and intestine, MTTP is expressed in cardiomyocytes, and cardiomyopathy has been reported in several ABL cases. Using induced pluripotent stem cells (iPSCs) generated from an ABL patient homozygous for a missense mutation (MTTPR46G), we show that human hepatocytes and cardiomyocytes exhibit defects associated with ABL disease, including loss of apolipoprotein B (apoB) secretion and intracellular accumulation of lipids. MTTPR46G iPSC-derived cardiomyocytes failed to secrete apoB, accumulated intracellular lipids, and displayed increased cell death, suggesting intrinsic defects in lipid metabolism due to loss of MTTP function. Importantly, these phenotypes were reversed after the correction of the MTTPR46G mutation by CRISPR/Cas9 gene editing. Together, these data reveal clear cellular defects in iPSC-derived hepatocytes and cardiomyocytes lacking MTTP activity, including a cardiomyocyte-specific regulated stress response to elevated lipids.

Citations

Jan 20, 2018·Current Opinion in Lipidology·Kiran Musunuru
Mar 7, 2018·Journal of Pediatric Gastroenterology and Nutrition·Sakil Kulkarni, David A Rudnick
Aug 5, 2018·Journal of Lipid Research·Nicholas N LyssenkoVenkata Ramana Murthy Chavali
May 31, 2018·Circulation. Genomic and Precision Medicine·Kiran MusunuruUNKNOWN American Heart Association Council on Genomic and Precision Medicine; Council on Cardiovascular Disease in the Young; Counci
Jan 29, 2019·Cardiovascular Research·Emily A PinheiroPaul W Burridge
Nov 20, 2019·Current Atherosclerosis Reports·Dirk J BlomA David Marais
Dec 2, 2020·Journal of Clinical Laboratory Analysis·Perla Graciela Rodríguez GutiérrezMaría Teresa Magaña Torres
Sep 19, 2019·Journal of Molecular and Cellular Cardiology·Martina KlevstigJan Borén
Jan 5, 2021·Advanced Functional Materials·Dantong HuangKam W Leong
Jun 11, 2021·Journal of Animal Physiology and Animal Nutrition·Yan DengJiwen Wang
Nov 30, 2018·Journal of Agricultural and Food Chemistry·Yanli LiuXiaojun Yang
Aug 28, 2021·International Journal of Molecular Sciences·Wei Sheng SiewWei Hsum Yap
Jan 5, 2022·DNA and Cell Biology·Lin YuLei Zhou

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.